Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 534

1.

Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss.

Gallagher JC, Fowler SE, Detter JR, Sherman SS.

J Clin Endocrinol Metab. 2001 Aug;86(8):3618-28.

PMID:
11502787
2.

Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers.

Gallagher JC, Rapuri PB, Haynatzki G, Detter JR.

J Clin Endocrinol Metab. 2002 Nov;87(11):4914-23.

PMID:
12414850
3.
4.

A 3-year study of prevention of postmenopausal bone loss: conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone.

ThiƩbaud D, Bigler JM, Renteria S, Pache T, Welti HJ, Landry M, Burckhardt P.

Climacteric. 1998 Sep;1(3):202-10.

PMID:
11907945
5.

A randomized trial comparing hormone replacement therapy (HRT) and HRT plus calcitriol in the treatment of postmenopausal osteoporosis with vertebral fractures: benefit of the combination on total body and hip density.

Gutteridge DH, Holzherr ML, Retallack RW, Price RI, Will RK, Dhaliwal SS, Faulkner DL, Stewart GO, Stuckey BG, Prince RL, Criddle RA, Drury PJ, Tran L, Bhagat CI, Kent GN, Jamrozik K.

Calcif Tissue Int. 2003 Jul;73(1):33-43.

PMID:
14506952
6.
7.

Alveolar and postcranial bone density in postmenopausal women receiving hormone/estrogen replacement therapy: a randomized, double-blind, placebo-controlled trial.

Civitelli R, Pilgram TK, Dotson M, Muckerman J, Lewandowski N, Armamento-Villareal R, Yokoyama-Crothers N, Kardaris EE, Hauser J, Cohen S, Hildebolt CF.

Arch Intern Med. 2002 Jun 24;162(12):1409-15. Erratum in: Arch Intern Med. 2004 Jan 12;164(1):96.

PMID:
12076241
8.
10.

Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.

Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW, McKeever C, Miller SS, Davidson M, Bolognese MA, Mulloy AL, Heyden N, Wu M, Kaur A, Lombardi A.

Ann Intern Med. 2002 Dec 3;137(11):875-83.

PMID:
12458987
11.
12.
13.

Prevention of postmenopausal bone loss by low and conventional doses of calcitriol or conjugated equine estrogen.

Ongphiphadhanakul B, Piaseu N, Tung SS, Chailurkit L, Rajatanavin R.

Maturitas. 2000 Feb 15;34(2):179-84.

PMID:
10714913
14.

Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.

Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ; MK-677/Alendronate Study Group..

J Clin Endocrinol Metab. 2001 Mar;86(3):1116-25.

PMID:
11238495
15.

Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.

Hosking D, Chilvers CE, Christiansen C, Ravn P, Wasnich R, Ross P, McClung M, Balske A, Thompson D, Daley M, Yates AJ.

N Engl J Med. 1998 Feb 19;338(8):485-92.

16.
17.

Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen.

Gallagher JC, Kable WT, Goldgar D.

Am J Med. 1991 Feb;90(2):171-8.

PMID:
1847582
18.

Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women.

Harris ST, Eriksen EF, Davidson M, Ettinger MP, Moffett Jr AH Jr, Baylink DJ, Crusan CE, Chines AA.

J Clin Endocrinol Metab. 2001 May;86(5):1890-7.

PMID:
11344179
19.

Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.

McClung MR, Wasnich RD, Recker R, Cauley JA, Chesnut CH 3rd, Ensrud KE, Burdeska A, Mills T; Oral Ibandronate Study Group..

J Bone Miner Res. 2004 Jan;19(1):11-8.

20.
Items per page

Supplemental Content

Support Center